Extended Data Table 4 Pharmacokinetic parameters of RAY1216 and PF-07321332 after intravenous injection (i.v.) dosing and gavage (p.o.) dosing in mouse and rat models

From: Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

  1. Data are shown as mean ± SD (n = 5).
  2. Source data
Back to article page